16 stories mentioning SHE:300765Updated 7h ago
Every FINWIRES story that references SHE:300765, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
CSPC Innovation Pharmaceutical (SHE:300765) subsidiary Jushi Biopharmaceutical presented Phase I/II data for SYS6010 at the 2026 World Conference on Lung Cancer in Seoul.Among 123 patients, confirmed objective response rates reached 58.9% and 49.2% for the two dosing regimens, according to a Monday aftermarket filing with the Shenzhen bourse.
CSPC Innovation Pharmaceutical's (SHE:300765) drug, SYS6010, was included in the Breakthrough Therapy Product List of China's National Medical Products Administration, according to a Shenzhen bourse filing on Tuesday.The Chinese pharmaceutical company's shares rose 2% during Wednesday's morning trade.The drug, which was developed by subsidiary Shijiazhuang CSPC Jushi Biopharmaceutical, is used for the treatment of patients with relapsed or metastatic head and neck squamous cell carcinoma who have failed to respond to immunotherapy and platinum-containing chemotherapy.
CSPC Innovation Pharmaceutical's (SHE:300765) subsidiary, CSPC Jushi Biopharmaceutical, started the phase I clinical trial of SYH2092 injection, according to a Shenzhen bourse filing late Monday.The drug is being developed for weight management in patients with obesity and to help improve glycemic control of adult patients with type 2 diabetes mellitus.The drug is undergoing testing to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SYH2092 in healthy participants.
CSPC Innovation Pharmaceutical's (SHE:300765) first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), received a fast track designation from the U.S. Food and Drug Administration, according to a Wednesday disclosure on the Shenzhen bourse.The Chinese pharmaceutical company's shares rose 4% during Thursday's afternoon trade.The drug is developed by the company's subsidiary, CSPC Giant Biopharmaceutical, as a treatment for patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer.
CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical's phase 3 trial for its SYS6010 lung cancer drug reached its primary endpoint of progression-free survival, according to a Thursday disclosure to the Shenzhen Stock Exchange.The drug exhibited better progression-free survival than current treatments, with statistically and clinically significant differences, as well as good safety, the filing said.
CSPC Innovation Pharmaceutical's (SHE:300765) subsidiary, CSPC Jushi Biopharmaceutical, initiated the phase Ib/II clinical trial of SYS6090 injection as a treatment for hepatocellular carcinoma, according to a Shenzhen bourse filing on Wednesday.The Chinese pharmaceutical company's shares slipped during Thursday's afternoon trade.The open-label, multicenter clinical trial looks into the safety and efficiency of the drug as a combination therapy.
CSPC Innovation Pharmaceutical (SHE:300765) recorded an attributable net profit of 1.26 billion yuan in the first half from an attributable net loss of 2.7 million yuan a year ago.EPS was 0.9056 yuan, compared with net loss per share of 0.002 yuan previously, according to a Shenzhen Stock Exchange filing on Tuesday.Operating revenue jumped 209% to 3.24 billion yuan from 1.05 billion yuan.
CSPC Innovation Pharmaceutical (SHE:300765), through unit Jushi Biosciences, received the initial payment of $30 million from AstraZeneca for the development of the small nucleic acid pipeline, according to a Wednesday disclosure on the Shenzhen bourse.The Chinese pharmaceutical company's shares rose 2% during Thursday's morning trade.Jushi Biosciences signed a deal with AstraZeneca in July to develop nucleic acids for drug production.
CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical received U.S. Food and Drug Administration clearance to conduct clinical trials of its SYS6037 monkeypox vaccine candidate.The investigational new drug application for the vaccine passed safety review by the U.S. FDA, according to an after-hours filing on Monday with the Shenzhen bourse.Shares jumped nearly 6% during afternoon trading on Tuesday.
CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical received U.S. Food and Drug Administration clinical trial approval for its CRB-701 drug, according to a Wednesday after-hours filing with the Shenzhen Stock Exchange.The drug received approval for its TEMPO-1 randomized controlled clinical trial for the drug targeting Nectin-4, an antigen expressed in urothelial carcinoma as well as in cervical cancer and head and neck squamous cell carcinoma.Shares fell 4% during afternoon trading on Thursday.
CSPC Innovation Pharmaceutical (SHE:300765) subsidiary Jushi Biopharmaceutical received approval from China's National Medical Products Administration for the phase 3 trial of its self-developed SYS6043 drug, according to a Thursday after-hours filing with the Shanghai Stock Exchange.SYS6043 is an antibody-drug conjugate that targets B7-H3 and releases a small molecule toxin to kill tumor cells, the company said in its filing.The trial will evaluate the response in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.Shares in the drug company fell 4% during afternoon trading on Friday.
CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical has launched a Phase III clinical trial for its cancer therapy, SYS6010, according to a Shenzhen Stock Exchange filing on Wednesday.The trial targets patients with resected stage II-IIIB driver gene-negative non-small cell lung cancer who did not achieve a major pathological response after previous treatment.SYS6010 is a novel antibody-drug conjugate approved by China's National Medical Products Administration in June.
CSPC Innovation Pharmaceutical (SHE:300765) on June 18 updated its H-share listing application with the Hong Kong Stock Exchange, according to a Monday filing with the Shenzhen bourse.The pharmaceutical company initially filed its application on Dec. 10, 2025.Shares of CSPC Innovation Pharmaceutical rose nearly 1% in recent trade.
CSPC Innovation Pharmaceutical (SHE:300765) unit CSPC Jushi Biopharmaceutical obtained the approval of China's medical products administrator to conduct clinical trials for SYS6041 in combination therapy for ovarian cancer.The potential indications for SYS6041 include solid tumors such as gynecological tumors and lung cancer, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 4% lower Tuesday.
CSPC Innovation Pharmaceutical (SHE:300765, HKG:1093) received drug registration from China's medical products administrator for ustekinumab injection.The drug, branded as Enyike, is used to treat moderate to severe plaque psoriasis, according to Friday filings with the Shenzhen and Hong Kong bourses.
